<div id="readability-page-1"><p>Gyre Therapeutics, Inc. (NASDAQ:GYRE - Get Free Report) CEO Ying Luo sold 10,136 shares of the firm's stock in a transaction on Wednesday, May 6th. The shares were sold at an average price of $8.04, for a total value of $81,493.44. Following the transaction, the chief executive officer owned 2,565,226 shares of the company's stock, valued at $20,624,417.04. The trade was a 0.39% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this hyperlink.</p><div><p><span></span><span>Get <strong>Gyre Therapeutics</strong> alerts:</span></p></div><h2>Gyre Therapeutics Price Performance</h2><p>Gyre Therapeutics stock traded down $0.97 during mid-day trading on Thursday, reaching $7.07. The stock had a trading volume of 167,488 shares, compared to its average volume of 55,514. Gyre Therapeutics, Inc. has a one year low of $6.57 and a one year high of $11.78. The company has a 50-day moving average price of $7.58 and a two-hundred day moving average price of $7.69. The company has a market capitalization of $685.72 million, a price-to-earnings ratio of 707.71 and a beta of 2.03. </p><p>Gyre Therapeutics (NASDAQ:GYRE - Get Free Report) last released its quarterly earnings data on Thursday, May 7th. The company reported ($0.10) earnings per share for the quarter, missing analysts' consensus estimates of ($0.06) by ($0.04). The firm had revenue of $22.52 million for the quarter, compared to the consensus estimate of $31.61 million. Gyre Therapeutics had a net margin of 4.31% and a return on equity of 10.85%.  On average, equities research analysts anticipate that  Gyre Therapeutics, Inc. will post -0.18 earnings per share for the current fiscal year. </p><h2>Wall Street Analysts Forecast Growth</h2><p>A number of equities analysts recently weighed in on GYRE shares. Wall Street Zen lowered shares of Gyre Therapeutics from a &#34;buy&#34; rating to a &#34;hold&#34; rating in a report on Saturday, March 14th. Weiss Ratings  reissued a &#34;sell (d)&#34; rating on shares of Gyre Therapeutics in a report on Thursday, January 22nd. Finally, Zacks Research cut Gyre Therapeutics from a &#34;hold&#34; rating to a &#34;strong sell&#34; rating in a research note on Monday, March 16th. Two equities research analysts have rated the stock with a Buy rating and two have given a Sell rating to the company. Based on data from MarketBeat.com, the company presently has an average rating of &#34;Hold&#34; and an average price target of $17.00.</p><p><b>View Our Latest Analysis on Gyre Therapeutics</b></p><h2>Institutional Investors Weigh In On Gyre Therapeutics</h2><p>A number of large investors have recently added to or reduced their stakes in GYRE. Dimensional Fund Advisors LP lifted its holdings in shares of  Gyre Therapeutics by 131.8% during the 1st quarter. Dimensional Fund Advisors LP now owns 25,268 shares of the company's stock valued at $176,000 after buying an additional 14,365 shares during the period.  Bank of New York Mellon Corp increased its position in  Gyre Therapeutics by 4.7% during the first quarter. Bank of New York Mellon Corp now owns 43,144 shares of the company's stock valued at $301,000 after acquiring an additional 1,941 shares during the last quarter.  Barclays PLC increased its position in  Gyre Therapeutics by 38.3% during the fourth quarter. Barclays PLC now owns 18,531 shares of the company's stock valued at $131,000 after acquiring an additional 5,135 shares during the last quarter.  Charles Schwab Investment Management Inc. lifted its holdings in  Gyre Therapeutics by 37.1% in the fourth quarter. Charles Schwab Investment Management Inc. now owns 169,158 shares of the company's stock valued at $1,194,000 after acquiring an additional 45,772 shares during the period.  Finally, State Street Corp lifted its holdings in  Gyre Therapeutics by 10.7% in the fourth quarter. State Street Corp now owns 202,225 shares of the company's stock valued at $1,428,000 after acquiring an additional 19,472 shares during the period. Institutional investors own  23.99% of the company's stock. </p><h2>About Gyre Therapeutics</h2> (Get Free Report)<p>Gyre Therapeutics, Inc is a clinical-stage biotechnology company focused on discovering and developing small-molecule therapies that target lipid biology to treat a range of metabolic, inflammatory and neurodegenerative diseases. The company's proprietary platform combines lipidomic profiling with drug discovery tools to identify compounds that selectively modulate membrane lipid composition and restore normal protein function in disease-relevant cells.  </p><p>Gyre's preclinical pipeline includes programs in nonalcoholic steatohepatitis (NASH), Alzheimer's disease and autoimmune conditions, reflecting its strategy of applying a unified lipid-targeted approach across multiple therapeutic areas.</p><h2>Featured Stories</h2><ul><li>Five stocks we like better than Gyre Therapeutics</li></ul><p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p><h2>Should You Invest $1,000 in Gyre Therapeutics Right Now?</h2><p>Before you consider Gyre Therapeutics, you'll want to hear this.</p><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Gyre Therapeutics wasn't on the list.</p><p>While Gyre Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.</p><p>View The Five Stocks Here</p>                  </div>

GYRE

<p>Ying Luo, CEO of Gyre Therapeutics (NASDAQ:GYRE), sold 10,136 shares at an average price of $8.04, totaling $81,493.44. Post-sale, he holds 2,565,226 shares valued at approximately $20.62 million, marking a 0.39% decrease in ownership. The sale was disclosed to the SEC. Gyre's stock recently traded at $7.07, with a market cap of $685.72 million. The company reported a quarterly loss of $0.10 per share, missing estimates. Analysts have mixed ratings on the stock, with an average target price of $17.00.</p>

Ying Luo Sells 10,136 Shares of Gyre Therapeutics (NASDAQ:GYRE) Stock